# DESCRIPTION

## FIELD

- introduce carrier-based dry powder formulations

## BACKGROUND

- describe respiratory tract anatomy
- explain particle deposition mechanisms
- discuss limitations of current dry powder formulations

## BRIEF SUMMARY

- summarize carrier-based dry powder formulations
- outline methods of preparing and using formulations

## DEFINITIONS

- define carrier-based dry powder formulation
- define active ingredient and related terms
- define fine and extrafine carrier particles
- define amorphous and crystalline states
- define various particle size and density terms

## DETAILED DESCRIPTION

- motivate targeted delivery to small airways
- describe limitations of conventional dry powder formulations
- introduce carrier-based dry powder formulations
- explain importance of impaction parameter for regional deposition
- describe relationship between da2Q and URT deposition
- discuss requirements for effective targeting to small airways
- introduce lung targeting index and peripheral lung index
- describe advantages of carrier-based dry powder formulations

### I. Carrier Particles

- introduce carrier-based dry powder formulations
- limitations of conventional carrier particles
- describe leucine carrier particles
- characterize fine and extrafine carrier particles
- discuss adhesive mixtures and MMIP
- summarize advantages and applications

### II. Formulations

- define carrier-based dry powder formulations
- describe advantages over conventional formulations
- summarize characteristics of drug particles and carrier particles
- introduce metrics for evaluating formulation performance

### III. Active Agent

- define active agent
- list examples of active agents
- list active agents
- categorize active agents by therapeutic area
- provide examples of oncology drugs
- list nucleic acid, peptide, and protein active agents
- provide examples of pharmaceutically active substances for inhalation
- list additional active agents
- describe application of methods to produce micron-sized or nano-sized crystals of poorly soluble hydrophobic drugs

### IV. Methods For Producing Formulations

- outline methods for preparing carrier-based dry powder formulations
- describe preparation of carrier particles
- detail spray-drying process for carrier particles
- describe preparation of drug particles
- outline bottom-up manufacturing processes for drug particles
- summarize solvent selection for drug solution
- define non-solvent properties
- describe homogeneous mixing of drug and carrier
- explain removing liquid non-solvent to form dry powder
- detail atomization process
- outline drying steps
- specify formulation composition

### V. Delivery System

- describe dry powder inhaler systems
- detail various types of dry powder inhalers
- specify features of breath-actuated inhalers

### VI. Methods of Use

- outline method of treating disease via inhalation
- describe methods for treating specific diseases
- detail methods for delivering formulations to small airways
- specify methods for aerosolizing carrier-based dry powder formulations
- highlight advantages of pulmonary delivery over oral administration

## EMBODIMENTS

- define carrier-based dry powder formulations
- specify particle sizes and properties
- describe methods of preparing formulations
- detail solvent and drying conditions
- outline administration methods and devices
- specify disease treatment applications

## EXAMPLES

- describe preparation of leucine carrier particles and their properties

### Example 1

- prepare leucine carrier particles with varying solids content
- determine physical properties of leucine carrier bulk powder

### Example 2

- prepare feedstock for ciclesonide powder for inhalation
- describe spray-drying process and particle properties
- perform assay testing and aerosol testing

### Example 3

- prepare neat ciclesonide particles and determine their properties

### Example 4

- investigate effect of mixing conditions on preparation of ciclesonide powder for inhalation

### Example 5

- prepare ciclesonide powders with varying drug loading and determine their properties

### Example 6

- discuss assay and blend uniformity of ciclesonide/leucine blends

### Example 7

- prepare fluticasone propionate formulations

### Example 8

- detail physicochemical properties of ciclesonide powder

### Example 9

- assess total lung dose of ciclesonide formulation
- describe experimental setup for aerosol testing
- detail TLD performance in ICT and AIT models
- evaluate flow rate independence of CPI batch
- assess environmental robustness of CPI batch
- compare moisture sorption isotherms of ciclesonide/leucine blend and DSPC:CaCl2
- discuss advantages of highly crystalline formulation
- illustrate TLD performance at elevated RH

